Loading
German oncologist who led FLOT4, the trial that made the FLOT chemotherapy regimen the standard before and after surgery for stomach and oesophago-gastric junction cancer.
Salah-Eddin Al-Batran directs the Institute of Clinical Cancer Research at Krankenhaus Nordwest in Frankfurt and led the German AIO group's FLOT4 trial. Its 2019 Lancet report, of which he was first author, showed that perioperative fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) lengthened survival compared with ECF or ECX in resectable gastric or gastro-oesophageal junction adenocarcinoma, replacing the older regimen across Europe.
| Title | Journal | Year |
|---|---|---|
| FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma | The Lancet | 2019 |
Shares FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tags oesophageal, trialist.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tags oesophageal, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Oesophageal cancer and the tags oesophageal, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.